This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Small-Cap Stocks Poised to Rise, History Shows (Update2)


10. Zoll Medical (ZOLL)

Company profile: Zoll, with a market value of $2 billion, makes medical equipment used to resuscitate victims of trauma or cardiac arrest.

Investor takeaway: Its shares are up 19% this year and 53% over the past three months, and have a three-year, average annual return of 88%.

Analysts give its shares four "buy" ratings, three "buy/holds," and one "hold," according to a survey of analysts by S&P.

Revenue has risen steadily over the past five years and, earnings, over three years. For fiscal 2012, analysts estimate Zoll Medical will earn $1.95 per share and that will grow by 36% to $2.65 in 2013.

9. Ista Pharmaceuticals (ISTA)

Company profile: Ista Pharmaceuticals, with a market value of $355 million, develops various drugs for the ophthalmic market. It is also working on allergy drugs.

Investor takeaway: Ista's shares are up 21% this year, including 116% in the past three months, and have a three-year, average annual return of 69%.

Analysts give the stock one "buy/hold" rating and three "holds," per S&P. For fiscal 2012, analysts estimate earnings will grow 312% to 33 cents per share. For 2011, the company reported a net loss of $57 million or $1.47 per share, but it had operating income of $2.28 per share.

8. Buffalo Wild Wings (BWLD)

Company profile: Buffalo Wild Wings, with a market value of $1.6 billion, is a casual dining restaurant chain that owns and franchises 560 restaurants in 38 states.

Investor takeaway: Buffalo Wild Wings' shares are up 32% this year, 42% over the past three months, and have a three-year, average annual return of 43%.

Analysts give them seven "buy" ratings, one "buy/holds," nine "holds," and one "sell," according to S&P. Analysts estimate it will earn $3.28 per share this year and that that will grow by 17% to $3.85 in 2013. Revenue, earnings and cash flow are up by double-digit amounts over the past five years.

7. Mako Surgical (MAKO)

Company profile: Mako Surgical, with a market value of $1.6 billion, develops a robotic device and implants for a minimally invasive knee procedure called the MAKOplasty.

Investor takeaway: Its shares are up 41% over the past three months and have a three-year average annual return of 77%. Analysts give them one "buy" rating, two "buy/holds," and five "holds," according to S&P.

6. Bio-Reference Labs (BRLI)

Company profile: Bio-Reference Labs, with a market value of $642 million, is a New Jersey-based company that performs chemical-diagnostic tests, including blood and urine analysis, hematology services, pap smears and other types of tests.

Investor takeaway: Its shares are up 42% this year, including 65% in the past three months, and have a three-year, average annual return of 29%. Analysts give the stock three "buy" ratings and two "holds," according to a survey of analysts by S&P.

Bio-Reference Labs expected to earn $1.45 per share this year, and that that will grow by 19% to $1.73 per share in 2013. The company has five years of steady revenue, earnings and cash flow growth.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,067.00 +13.29 0.07%
S&P 500 2,092.26 +3.49 0.17%
NASDAQ 4,809.1940 +2.3350 0.05%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs